Silo Pharma Inc (SILO) News

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

Proposal submitted for FDA 505(b)(2) regulatory pathway for SPC-15 approval Advancing path to IND submission...

Form EFFECT - Notice of Effectiveness

Form S-1 - General form for registration of securities under the Securities Act of 1933

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

SP-26 dissolvable ketamine-based injectable implant targets chronic pain and fibromyalgia Sever Pharma to...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Silo to advance homing peptide development for initial indication in multiple sclerosis SARASOTA, FL, Aug. 07...

Form D - Notice of Exempt Offering of Securities

Form EFFECT - Notice of Effectiveness

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

Presentation to feature Silo’s novel therapeutics for the underserved SARASOTA, FL, July 26, 2024 (GLOBE...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 8-K - Current report

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SARASOTA, FL, July 22, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a...